Anti-angiogenic drugs

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Angiogenesis or neovascularization, the formation of neo-vessels, is a physiological phenomenon endued in vasculature, but is involved in various pathological conditions. Angiogenesis is required for tumor growth and metastasis, and thus constitutes an important target for the control of tumor progression. Indeed, the recent development of bevacizumab, a neutralizing anti-VEGF monoclonal antibody as the first anti-angiogenic drug, legalized the clinical merit of anti-angiogenesis in cancers. Thereafter, various drugs targeting VEGF-mediated signals have been developed to control tumor angiogenesis. Thus, anti-angiogenic drugs are now recognized in the clinic as a major step forward for the treatment of cancers. This review focuses on the current status of antiangiogenesis treatment in cancers.

Original languageEnglish
Pages (from-to)1054-1058
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume68
Issue number6
Publication statusPublished - 2010 Jun

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anti-angiogenic drugs'. Together they form a unique fingerprint.

Cite this